Joinn Laboratories(China)Co Asset Resilience Ratio
Joinn Laboratories(China)Co asset resilience ratio. Joinn Laboratories(China)Co (603127) has an Asset Resilience Ratio of 15.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Joinn Laboratories(China)Co defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Joinn Laboratories(China)Co (2017–2025)
Asset resilience ratio of Joinn Laboratories(China)Co from 2017 to 2025. This chart shows how Joinn Laboratories(China)Co's Asset Resilience Ratio has changed over time. Read 603127 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Joinn Laboratories(China)Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Joinn Laboratories(China)Co (603127) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.51 Billion | 15.05% |
| Total Liquid Assets | CN¥1.51 Billion | 15.05% |
Asset Resilience Insights
- Good Liquidity Position: Joinn Laboratories(China)Co maintains a healthy 15.05% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Joinn Laboratories(China)Co Industry Peers by Asset Resilience Ratio
Compare Joinn Laboratories(China)Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang DiAn Diagnostics Co
SHE:300244 |
Diagnostics & Research | 3.61% |
|
Shanghai Runda Med Tech Co
SHG:603108 |
Diagnostics & Research | 0.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Lumibird SA
PA:LBIRD |
Diagnostics & Research | 22.85% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.71% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
Joinn Laboratories(China)Co Asset Resilience Ratio by Year (2017–2025)
Joinn Laboratories(China)Co asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Joinn Laboratories(China)Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.75% | CN¥1.72 Billion ≈ $251.44 Million |
CN¥9.68 Billion ≈ $1.42 Billion |
+2.89pp |
| 2024-12-31 | 14.86% | CN¥1.40 Billion ≈ $204.30 Million |
CN¥9.40 Billion ≈ $1.37 Billion |
+11.14pp |
| 2023-12-31 | 3.72% | CN¥373.35 Million ≈ $54.63 Million |
CN¥10.03 Billion ≈ $1.47 Billion |
-0.22pp |
| 2022-12-31 | 3.94% | CN¥408.47 Million ≈ $59.77 Million |
CN¥10.36 Billion ≈ $1.52 Billion |
-4.04pp |
| 2021-12-31 | 7.98% | CN¥680.98 Million ≈ $99.65 Million |
CN¥8.54 Billion ≈ $1.25 Billion |
-3.36pp |
| 2020-12-31 | 11.33% | CN¥238.90 Million ≈ $34.96 Million |
CN¥2.11 Billion ≈ $308.44 Million |
+2.12pp |
| 2019-12-31 | 9.22% | CN¥130.70 Million ≈ $19.13 Million |
CN¥1.42 Billion ≈ $207.47 Million |
+0.21pp |
| 2018-12-31 | 9.01% | CN¥102.85 Million ≈ $15.05 Million |
CN¥1.14 Billion ≈ $167.02 Million |
+8.96pp |
| 2017-12-31 | 0.06% | CN¥519.97K ≈ $76.09K |
CN¥940.87 Million ≈ $137.68 Million |
-- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more